AZA treatment alone or in combination with other epigenetic inhibitors improves the therapeutic efficacy of anti-PD-L1 and anti-CTLA4 treatments in mouse models of melanoma and ovarian cancer [25,26]. Here, CD274 is linked to ovarian cancer.